Table 2.
Disease specificity of GAD autoantibodies.
| Subject | Prevalence |
|---|---|
| Healthy control | <1% |
| Acute-onset type 1 diabetes (at onset) | 60–80% |
| Fulminant type 1 diabetes | 5–9% |
| LADA (SPIDDM) | 100% |
| Type 2 diabetes (diet/OHA) | 4–5% |
| Polyglandular autoimmune syndrome, type 1 | 30–40% |
| Polyglandular autoimmune syndrome, type 2 | 30–50% |
| Autoimmune thyroid disease | 6–8% |
| Stiff-person syndrome | 60–70% |
LADA, latent-autoimmune diabetes in adults; SPIDDM, slowly progressive insulin-dependent diabetes; OHA, oral hypoglycemic agents.